Evidence map›Paper›PMID 37383687›Full record

ArticleRSC advances2023

Continuous microfluidic flow-through protocol for selective and image-activated electroporation of single cells.

Felix Pfisterer, Neus Godino, Tobias Gerling, Michael Kirschbaum

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Felix PfistererFraunhofer Institute for Cell Therapy and Immunology IZI, Branch Bioanalytics and Bioprocesses IZI-BB Am Muehlenberg 13 14476 Potsdam Germany michael.kirschbaum@izi-bb.fraunhofer.de.ORCID https://orcid.org/0000-0001-7508-0701
Neus GodinoFraunhofer Institute for Cell Therapy and Immunology IZI, Branch Bioanalytics and Bioprocesses IZI-BB Am Muehlenberg 13 14476 Potsdam Germany michael.kirschbaum@izi-bb.fraunhofer.de.ORCID https://orcid.org/0000-0002-5836-2608
Tobias GerlingFraunhofer Institute for Cell Therapy and Immunology IZI, Branch Bioanalytics and Bioprocesses IZI-BB Am Muehlenberg 13 14476 Potsdam Germany michael.kirschbaum@izi-bb.fraunhofer.de.ORCID https://orcid.org/0000-0002-1887-8175
Michael KirschbaumFraunhofer Institute for Cell Therapy and Immunology IZI, Branch Bioanalytics and Bioprocesses IZI-BB Am Muehlenberg 13 14476 Potsdam Germany michael.kirschbaum@izi-bb.fraunhofer.de.ORCID https://orcid.org/0000-0003-3686-8349
Fraunhofer Institute for Cell Therapy and Immunology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Electroporation of cells is a widely-used tool to transport molecules such as proteins or nucleic acids into cells or to extract cellular material. However, bulk methods for electroporation do not offer the possibility to selectively porate subpopulations or single cells in heterogeneous cell samples. To achieve this, either presorting or complex single-cell technologies are required currently. In this work, we present a microfluidic flow protocol for selective electroporation of predefined target cells identified in real-time by high-quality microscopic image analysis of fluorescence and transmitted light. While traveling through the microchannel, the cells are focused by dielectrophoretic forces into the microscopic detection area, where they are classified based on image analysis techniques. Finally, the cells are forwarded to a poration electrode and only the target cells are pulsed. By processing a heterogenically stained cell sample, we were able to selectively porate only target cells (green-fluorescent) while non-target cells (blue-fluorescent) remained unaffected. We achieved highly selective poration with >90% specificity at average poration rates of >50% and throughputs of up to 7200 cells per hour.

Identifiers

PMID37383687
PMCPMC10294288
OpenAlexW4382464400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.